Shenzhen Hepalink Pharmaceutical Group Co Ltd (Hepalink Group), is a pharmaceutical company that manufactures and distributes pharmaceutical APIs and products. The company offers heparin sodium active pharmaceutical ingredients, sodium preparations, pancreatin products, anticoagulant and antithrombotic drugs and sodium injections. Hepalink Group's offering services include contract development and manufacturing organization (CDMO) services, process development services, development support services, and manufacturing services. Hepalink is headquartered in Shenzhen, Guangdong, China.
Headquarters
China
Address
No. 19, Hi-Tech Zhongyi Avenue, Middle Area, Hi-Tech Zone , Nanshan Dist, Shenzhen, Guangdong, 518057
Website
www.hepalink.com
Telephone
86 755 26980311
No of Employees
2,366
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002399 (SHE)
Revenue (2022)
$1.1B
12.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
202%
(2022 vs 2021)
Market Cap*
$1.6B
Net Profit Margin (2022)
XYZ
168.8%
(2022 vs 2021)
* As of and is in US$
Shenzhen Hepalink Pharmaceutical Group Co Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| API | CDMO Services |
| Heparin Sodium | |
| Enoxaparin Sodium | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, OncoVent entered into a license agreement with Orient EuroPharma Co for the commercialization of oregovomab in Taiwan. |
| 2022 | Contracts/Agreements | In May, Cytovance Biologics and Avantor entered into a partnership, under which Avantor will strength Saiwan Biotech's cGMP plasmid production capabilities. |
| 2022 | Contracts/Agreements | In May, Cytovance Biologics, Inc and Cytovance Biologics, Inc to jointly provide batches of DNA plasmid products for biopharmaceutical customers. |
Competitor Comparison
| Key Parameters | Shenzhen Hepalink Pharmaceutical Group Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Livzon Pharmaceutical Group Co Ltd | Zhejiang Hisun Pharmaceutical Co Ltd | Beijing Tiantan Biological Products Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shenzhen | Shanghai | Zhuhai | Taizhou | Beijing |
| State/Province | Guangdong | Shanghai | Guangdong | Zhejiang | Beijing |
| No. of Employees | 2,366 | 38,399 | 9,005 | 8,325 | 4,568 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li Li | Chairman | Executive Board | 2007 | 59 |
| Sun Xuan | Vice Chairman | Executive Board | 2020 | 47 |
| Li Tan | Deputy General Manager; Director | Executive Board | 2007 | 58 |
| Shan Yu | General Manager; Director | Executive Board | 2007 | 63 |
| Xiang Xianqing | Chief Financial Officer | Senior Management | 2022 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward